Gepotidacin API (CAS No. 1075236-89-3) is a synthetic first-in-class triazaacenaphthylene antibacterial active pharmaceutical ingredient associated with novel antibiotic, urinary tract infection, anti-infective, and bacterial topoisomerase inhibitor pharmaceutical development.
Gepotidacin, also known by the development code GSK2140944, represents a novel class of antibacterial pharmaceutical compounds.
Unlike fluoroquinolone antibacterial agents, Gepotidacin interacts with bacterial type II topoisomerases through a distinct binding mechanism.
Gepotidacin inhibits bacterial DNA gyrase and bacterial topoisomerase IV, two essential enzymes involved in bacterial DNA replication.
DNA gyrase is involved in maintaining appropriate bacterial DNA topology during replication and transcription.
Topoisomerase IV contributes to separation of replicated bacterial chromosomes.
By inhibiting these bacterial type II topoisomerase enzymes, Gepotidacin disrupts bacterial DNA replication and contributes to bactericidal antibacterial activity against susceptible microorganisms.
The novel chemical scaffold and distinct topoisomerase-binding characteristics of Gepotidacin are particularly important in antibacterial drug development and antimicrobial resistance research.
Gepotidacin is associated with oral antibacterial pharmaceutical products for uncomplicated urinary tract infections caused by susceptible microorganisms.
Pharmaceutical companies sourcing Gepotidacin API commonly evaluate assay, HPLC purity, stereochemical identity, related substances, process-related impurities, degradation products, residual solvents, water content, crystal form, polymorphic characteristics, particle size distribution, and batch-to-batch consistency.
Gepotidacin contains a defined stereocenter. Therefore, stereochemical identity and control of stereoisomeric impurities may be important during API qualification and pharmaceutical development.
Gepotidacin free compound and Gepotidacin Mesylate should be treated as separate pharmaceutical material identities.
The marketed pharmaceutical material is associated with Gepotidacin Mesylate Dihydrate. Procurement, quality, formulation, and regulatory teams should confirm the exact free compound, mesylate, or hydrated salt form before commercial sourcing.
Swapnroop Drugs and Pharmaceuticals supplies Gepotidacin API for qualified pharmaceutical research, antibacterial drug development, urinary tract infection formulation development, analytical requirements, novel antibiotic research, and regulated pharmaceutical manufacturing requirements with product-specific quality documentation, pharmaceutical-grade packaging, and reliable supply-chain coordination.
Gepotidacin API is primarily associated with:
Gepotidacin-related oral pharmaceutical products are associated with treatment of uncomplicated urinary tract infections caused by susceptible microorganisms.
Gepotidacin represents a novel antibacterial pharmaceutical approach for urinary tract infection development.
The antibacterial mechanism differs from established fluoroquinolone topoisomerase inhibitors because Gepotidacin interacts with bacterial type II topoisomerases through a distinct binding site.
Pharmaceutical companies evaluating Gepotidacin API may review:
Product-specific API specifications should be evaluated according to the exact Gepotidacin material form, intended dosage form, formulation process, target regulatory market, and approved pharmaceutical development requirements.
Gepotidacin is a bacterial type II topoisomerase inhibitor.
The compound inhibits bacterial DNA gyrase and topoisomerase IV.
DNA gyrase and topoisomerase IV are essential bacterial enzymes required for normal DNA replication and chromosome processing.
Gepotidacin interacts with these enzymes through a binding mechanism distinct from conventional fluoroquinolone antibacterial agents.
Inhibition of bacterial type II topoisomerases disrupts DNA replication.
This disruption contributes to bactericidal antibacterial activity against susceptible bacterial microorganisms.
Balanced inhibition of DNA gyrase and topoisomerase IV is an important characteristic of the Gepotidacin antibacterial mechanism.
Gepotidacin and Gepotidacin Mesylate should be treated as separate pharmaceutical material identities for website, procurement, quality, and specification purposes.
Gepotidacin free compound has CAS No. 1075236-89-3.
Its molecular formula is C24H28N6O3 and its molecular weight is approximately 448.52 g/mol.
Gepotidacin Mesylate Dihydrate is associated with CAS No. 1624306-20-2.
The molecular formula of Gepotidacin Mesylate Dihydrate is C24H28N6O3·CH4O3S·2H2O.
Its molecular weight is approximately 580.66 g/mol.
The mesylate dihydrate form is associated with the pharmaceutical material used in oral Gepotidacin products.
Procurement, formulation, quality, and regulatory teams should confirm whether Gepotidacin free compound or Gepotidacin Mesylate Dihydrate is required before commercial sourcing.
Antimicrobial resistance is a major consideration in modern antibacterial pharmaceutical development.
Gepotidacin has attracted pharmaceutical research interest because of its novel chemical scaffold and distinct bacterial topoisomerase binding mechanism.
Research and development considerations may include:
The exact antibacterial application and susceptibility requirements should be evaluated according to approved labeling and applicable microbiological standards.
Gepotidacin-related pharmaceutical products are associated with oral solid dosage forms.
Formulation-development considerations may include:
For development of conventional Gepotidacin oral pharmaceutical products, Gepotidacin Mesylate Dihydrate material specifications should be separately evaluated.
Swapnroop Drugs and Pharmaceuticals supports qualified pharmaceutical and antibacterial drug-development customers with:
Gepotidacin API is supplied in secure pharmaceutical-grade packaging selected according to product form, quantity, stability requirements, moisture-protection requirements, and customer specifications.
Product-appropriate pharmaceutical-grade inner liners and approved outer containers or HDPE drums may be used according to the supplied material specification.
Available packaging configurations may include:
Packaging configuration, MOQ, commercial quantity, crystal-form requirements, hydrate requirements, particle size requirements, and shipment conditions are confirmed according to the approved product specification and customer enquiry.
Get Bulk Quote via WhatsApp